Free Trial

China Reports 1st Covid-19 Vaccine Patent

CHINA PRESS
MNI (Sydney)

China reported its first patent of a vaccine against the Covid-19 virus which can be mass-produced, the Beijing Youth Daily reported on Monday. Named Ad5-nCoV, the vaccine was developed by a research team led by Chen Wei at the Military Science Academy in conjunction with CanSino Biologics. The vaccine has proved its efficacy in previous trials and is entering phase III clinical trails, reported the Daily.

MNI Sydney Bureau | +61-405-322-399 | lachlan.colquhoun.ext@marketnews.com
MNI Sydney Bureau | +61-405-322-399 | lachlan.colquhoun.ext@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.